Not logged in.png)
Share.png)
SaveShare Save Share Save Site-Specific Glycan Conjugation Improves Stability and Efficacy of an Antibody-Drug Conjugates Bearing DXd as a Cytotoxic Payload
Manabe, Shino; Senga, Shogo; Iwamoto, Shogo; Yarita, Hikaru; Takahashi, Ryo; Mitani, Ai; Sumiyoshi, Wataru; Hoshinoo, Asako; Hiranyakorn, Methanee; Kinoshita, Takashi; Yoshimura, Chihoko Share Save Share Save Share Save The anti-tumor effect of trifluridine via induction of aberrant mitosis is unaffected by mutations modulating p53 activityWakasa, Takeshi; Nonaka, Kentaro; Harada, Akihito; Ohkawa, Yasuyuki; Kikutake, Chie; Suyama, Mikita; Kobunai, Takashi; Tsunekuni, Kenta; Matsuoka, Kazuaki; Kataoka, Yuki; Ochiiwa, Hiroaki; Miyadera, Kazutaka; Sagara, Takeshi; Oki, Eiji; Ohdo, Shigehiro; Maehara, Yoshihiko; Iimori, Makoto; Kitao, Hiroyuki Share Save TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancerYoshida, Shohei; Kajiwara, Daisuke; Seki, Masanao; Tayama, Manabu; Tanaka, Yuki; Mizutani, Hiroya; Fujita, Ryoto; Yamamura, Keisuke; Okajima, Shigeo; Asai, Masanori; Minamiguchi, Kazuhisa Share Save Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)Day, James E. H.; Berdini, Valerio; Castro, Joan; Chessari, Gianni; Davies, Thomas G.; Day, Philip J.; St. Denis, Jeffrey D.; Fujiwara, Hideto; Fukaya, Satoshi; Hamlett, Christopher C. F.; Hearn, Keisha; Hiscock, Steven D.; Holvey, Rhian S.; Ito, Satoru; Kandola, Navrohit; Kodama, Yasuo; Liebeschuetz, John W.; Martins, Vanessa; Matsuo, Kenichi; Mortenson, Paul N.; Muench, Sandra; Nakatsuru, Yoko; Ochiiwa, Hiroaki; Palmer, Nicholas; Peakman, Torren; Price, Amanda; Reader, Michael; Rees, David C.; Rich, Sharna J.; Shah, Alpesh; Shibata, Yoshihiro; Smyth, Tomoko; Twigg, David G.; Wallis, Nicola G.; Williams, Glyn; Wilsher, Nicola E.; Woodhead, Andrew; Shimamura, Tadashi; Johnson, Christopher N. Share Save Share Save Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal CancerSunakawa, Yu; Kuboki, Yasutoshi; Watanabe, Jun; Terazawa, Tetsuji; Kawakami, Hisato; Yokota, Mitsuru; Nakamura, Masato; Kotaka, Masahito; Sugimoto, Naotoshi; Ojima, Hitoshi; Oki, Eiji; Kajiwara, Takeshi; Yamamoto, Yoshiyuki; Tsuji, Yasushi; Denda, Tadamichi; Tamura, Takao; Ishihara, Soichiro; Taniguchi, Hiroya; Nakajima, Takako Eguchi; Morita, Satoshi; Shirao, Kuniaki; Takenaka, Naruhito; Ozawa, Daisuke; Yoshino, Takayuki Share Save Share Save Share Save TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor ModelsIchikawa, Koji; Ito, Satoshi; Kato, Emi; Abe, Naomi; Machida, Takumitsu; Iwasaki, Junya; Tanaka, Gotaro; Araki, Hikari; Wakayama, Kentaro; Jona, Hideki; Sugimoto, Tetsuya; Miyadera, Kazutaka; Ohkubo, Shuichi Share Save Phase Ib study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Updated results of antitumor activity and tolerability results in combination with chemotherapyYamamoto, S.; Muro, K.; Nishino, K.; Kawakami, H.; Kojima, T.; Ojima, H.; Tanaka, Y.; Suyama, K.; Machida, N.; Koyanagi, K.; Iijima, K.; Hirai, H.; Chisamore, M.; Chin, K. Share Save Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutationsMiyazaki, Isao; Odintsov, Igor; Ishida, Keiji; Lui, Allan J. W.; Kato, Masanori; Suzuki, Tatsuya; Zhang, Tom; Wakayama, Kentaro; Kurth, Renate I.; Cheng, Ryan; Fujita, Hidenori; Delasos, Lukas; Vojnic, Morana; Khodos, Inna; Yamada, Yukari; Ishizawa, Kota; Mattar, Marissa S.; Funabashi, Kaoru; Chang, Qing; Ohkubo, Shuichi; Yano, Wakako; Terada, Ryuichiro; Giuliano, Claudio; Lu, Yue Christine; Bonifacio, Annalisa; Kunte, Siddharth; Davare, Monika A.; Cheng, Emily H.; de Stanchina, Elisa; Lovati, Emanuela; Iwasawa, Yoshikazu; Ladanyi, Marc; Somwar, Romel Share Save A phase I, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinibGao, Ling; Yamamiya, Ikuo; Pinti, Mark; Rondon, Juan Carlos; Marbury, Thomas; Tomlinson, Gareth; Makris, Lukas; Hangai, Nanae; Wacheck, Volker Share Save Share Save Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapyShibutani, Toshihiro; Goto, Risa; Miyazaki, Isao; Hashimoto, Akihiro; Suzuki, Takamasa; Ishida, Keiji; Haruma, Tomonori; Osada, Toshihiro; Harada, Takafumi; Fujita, Hidenori; Ohkubo, Shuichi Share Save Better Peptides via Chemical Glycosylation: Somatostatin Analogues Having a Human Complex-Type N-Glycan with Improved Drug PropertiesOchiai, Hirofumi; Shimoda, Taiji; Fukae, Kazuhiro; Maeda, Masatoshi; Ishii, Kazuyuki; Yoshida, Kenta; Tezuka, Katsunari; Tazuru, Keisuke; Saijo, Hayato; Asai, Hiroaki; Kanatani, Akio; Nishiuchi, Yuji Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
